FemtoMax 超敏HRP底物,輕松檢測飛克級別的抗原

FemtoMax 超靈敏化學發光HRP底物是一種極其靈敏、無放射性、增強型基于魯米諾化學發光底物,用于檢測辣根過氧化物酶(HRP)。FemtoMax 設計用于蛋白質印跡(WB)和酶聯免疫吸附測定(ELISA)。FemtoMax 可以使用照相膠片或其他成像方法(包括高靈敏度CCD相機)輕松檢測飛克級別的抗原??梢詫⒂≯E重復暴露于X射線膠片以獲得Z佳結果,或者剝離檢測試劑并重新檢測。在使用FemtoMax 時可使用與Amersham ECL Plus 底物或Pierce SuperSignal West Femto底物相同的印跡條件。

 

產品詳情:

產品描述: 用于微孔板&膜的化學發光FemtoMax?超敏HRP底物
貨號 FEMTOMAX-020
規格 20 mL
應用類型 WB, ELISA
物理狀態 液體-透明,無色,無味
儲存條件 4℃,防潮和避光

?

FemtoMax (貨號:FEMTOMAX-020)應用實例展示:

Elisa實驗:

不同組的血漿MDS-OAβ的濃度檢測:將孵育的血漿樣品混合物和連續稀釋的標準樣品加入各自的孔中,并將板在室溫下孵育1小時。然后,加入100μL/孔的增強化學發光底物溶液(p/n Femtomax),并使用Victor 3TM多分光光度計檢測相對發光單元(RLU)信號。PMID: 33958861
Korean version of Consortium to Establish a Registry for Alzheimer’s disease(CERAD-K)和血漿低聚β淀粉樣蛋白(OAβ)的測試:(a) CERAD-K和OAβ濃度的原始分數。(b)與對照組相比,言語流利度、命名、單詞記憶/回憶和總分異常的CERAD組(年齡/性別/教育,調整標準差低于?1.5)的OAβ濃度更高。(c) 高OAβ組(≥0.78 ng/mL)在命名、單詞記憶/回憶/識別和總分方面的異常明顯更常見。PMID: 32326061

?

Western Blot實驗:

CK2.3對RANKL誘導的破骨細胞生成中p-Erk1/2的影響:CK2.3在RAW264.7細胞中刺激24小時后增加p-Erk 1/2,如(A)蛋白質印跡所測定的。將印跡在3%BSA中孵育1小時以封閉非特異性結合??贵w以1:1000稀釋液(在1%BSA中)在4°C下過夜使用。隨后與HRP抗兔二抗以1:5000稀釋液(在1%BSA中)孵育。印跡在化學發光FemtoMax超敏HRP底物(p/n FemtoMax)中孵育2分鐘。PMID:3260129
使用Femtomax的小鼠抗AKT pS473抗體的蛋白質印跡:泳道1:未處理細胞中的非磷酸化AKT。泳道2:PDGF刺激的NIH/3T3細胞裂解物上磷酸化的AKT(用箭頭指示在~56kDa處)。上樣量:每泳道10μg。一抗:AKT pS473抗體,1:10000,TBS,含0.05%?Tween-20和1%BSA,在4°C下1小時。二抗:HRP標記的Gt-a-Mouse IgG(p/n 610-103-121),以1:20000稀釋,在4℃下與化學發光FemtoMax?超敏HRP底物(p/n FemtoMax-100)一起使用1小時。批號:25245AB
抗GST標簽抗體的蛋白質印跡:泳道1:重組GST標記的重組蛋白5μg;泳道2:重組GST-標記的重組蛋白質2μg;泳道3:重組GST標記的重組蛋白1ug。泳道4:重組GST標記的重組蛋白500 ng。泳道5:重組GST標記的重組蛋白250 ng。泳道6:重組GST標記的重組蛋白100 ng。泳道7:重組GST標記的重組蛋白50 ng。一抗:抗gst抗體,1:1000,在4℃下過夜。二抗:驢二抗,1:10000,室溫45分鐘。封閉:5%BLOTTO,4°C過夜。預測/觀測大?。?8 kDa。
使用化學發光FemtoMax?HRP底物進行蛋白質印跡檢測:rPARP1結構域在4°C下使用一抗兔血清1:500過夜曝光3秒后在11 kDa處檢測到。二抗HRP山羊抗兔IgG抗體1:40000。所有孵育均在用于熒光蛋白封閉的封閉緩沖液(p/n MB‐070)中進行。
化學發光FemtoMax?超靈敏HRP底物和競爭對手的比較:GAPDH蛋白以1000、250、62.5、15.6ngs的上樣量點在硝化纖維膜上。將膜在室溫下封閉一小時。一抗:Rb抗GAPDH1:2000稀釋,在4°C下孵育過夜。洗滌后,二抗:Gt抗Rb IgG HRP在室溫下以1:50000稀釋孵育2小時。檢測:化學發光FemtoMax?超敏HRP底物Vs競爭對手1-4。

?

FemtoMax (貨號:FEMTOMAX-020)引文展示:

  1. Mollin M?et al.(2021).?Clinical, functional and genetic characterization of 16 patients suffering from chronic granulomatous disease variants – identification of 11 novel mutations in CYBB.?Clin Exp Immunol.
  2. Bakri FG?et al.(2021).?Second Report of Chronic Granulomatous Disease in Jordan: Clinical and Genetic Description of 31 Patients From 21 Different Families, Including Families From Lybia and Iraq.?Front Immunol.
  3. Pyun JM?et al.(2021).?Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity.?Clinical Interventions in Aging
  4. Kim MK?et al.(2021).?A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression.?Biomed Pharmacother.
  5. Zhang L?et al.(2020).?Functional analysis of miR-767-5p during the progression of hepatocellular carcinoma and the clinical relevance of its dysregulation.?Histochem Cell Biol.
  6. Nguyen J?et al.(2020).?A Synthetic Peptide, CK2. 3, Inhibits RANKL-Induced Osteoclastogenesis through BMPRIa and ERK Signaling Pathway.?J Dev Biol.
  7. Durbano HW?et al.(2020).?Aberrant BMP2 Signaling in Patients Diagnosed with Osteoporosis.?Int J Mol Sci.
  8. Youn YC.?et al.(2020).?Blood Amyloid-β Oligomerization as a Biomarker of Alzheimer's Disease: A Blinded Validation Study.?J Alzheimers Dis.
  9. Brault J.?et al.(2020).?NOX4 is the main NADPH oxidase involved in the early stages of hematopoietic differentiation from human induced pluripotent stem cells.?Free Radic Biol Med.
  10. Lee JJ?et al.(2020).?Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer's Disease in Health Screening Population.?Diagnostics (Basel, Switzerland)
  11. Grafen A?et al.(2019).?Use of acid ceramidase and sphingosine kinase inhibitors as antiviral compounds against measles virus infection of lymphocytes in vitro.?Front Cell Dev Biol
  12. John V?et al.(2019).?Caveolin-1 controls vesicular TLR2 expression, p38 signaling and T cell suppression in BCG infected murine monocytic myeloid-derived suppressor cells.?Front Immunol.
  13. Chung?et al.(2018).?Niche-mediated BMP/SMAD signaling regulates lung alveolar stem cell proliferation and differentiation.?Development
  14. Kim TH?et al.(2018).?Additive effects of evogliptin in combination with pioglitazone on fasting glucose control through direct and indirect hepatic effects in diabetic mice.?Eur J Pharmacol.
  15. Tiwarekar V?et al.(2018).?APOBEC3G-regulated host factors interfere with measles virus replication: role of REDD1 and mammalian TORC1 inhibition.?J Virol.
  16. Dietrich K?et al.(2018).?Health-Relevant Phenotypes in the Offspring of Mice Given CAR Activators Prior to Pregnancy.?Drug Metab Dispos.
  17. Barfeld SJ?et al.(2017).?c-Myc antagonises the transcriptional activity of the androgen receptor in prostate cancer affecting key gene networks.
  18. An SSA?et al.(2017).?Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42.?Alzheimer's Research & Therapy
  19. Wang MJ?et al.(2017).?Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.?Alzheimer's Research & Therapy
  20. Tadokoro T?et al.(2016).?BMP signaling and cellular dynamics during regeneration of airway epithelium from basal progenitors.
  21. Wache C?et al.(2015).?Myeloid-related protein 14 promotes inflammation and injury in meningitis.?J Infect Dis.
  22. Carter LG?et al.(2015).?Exercise improves glucose disposal and insulin signaling in pregnant mice fed a high fat diet.?J Diabetes Metab.
  23. Beaumel S?et al.(2014).?Identification of NOX2 regions for normal biosynthesis of cytochrome b558 in phagocytes highlighting essential residues for p22phox binding.?Biochem J.
  24. Hohne C?et al.(2013).?High mobility group box 1 prolongs inflammation and worsens disease in pneumococcal meningitis.
  25. Huang BW?et al.(2013).?Transcriptional regulation of the human ferritin gene by coordinated regulation of Nrf2 and protein arginine methyltransferases PRMT1 and PRMT4.?FASEB J.
艾美捷科技優勢代理品牌

發表評論

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen: